Cartesian Therapeutics, Inc. (RNAC)
NASDAQ:RNAC
Want to see RNAC full AI Analyst Report?
Top Page
Cartesian Therapeutics
(NASDAQ:RNAC)
Select Model
Select Model
Rating:52Neutral
Price Target:
$9.50
▲(34.94% Upside)
Action:Reiterated
Date:06/13/26
The score is held down primarily by weak financial performance (shrinking revenue, large losses, negative equity, and heavy cash burn indicating ongoing funding needs). Technicals are a key positive with strong price momentum above major moving averages, while valuation is constrained by a negative P/E tied to loss-making operations. Recent corporate events modestly improve the outlook via added runway and partnering progress, but they do not remove core balance-sheet and cash-burn risks.
Positive Factors
Strategic licensing alliance (in‑vivo CAR‑T)
The WestGene licensing deal creates a structural shift from ex vivo to in vivo CAR‑T approaches, potentially simplifying manufacturing and accelerating clinical translation. That broadens Cartesian’s platform, reduces manufacturing complexity for select programs, and can lower long‑term cost and time to market.
Negative Factors
Persistent heavy cash burn and losses
Sustained negative operating and free cash flow at scale indicates reliance on external financing for core operations and trials. Over multiple quarters this magnifies funding risk, forces prioritization of programs, and increases the probability of dilution or restrictive financing terms absent material clinical or partnership breakthroughs.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic licensing alliance (in‑vivo CAR‑T)
The WestGene licensing deal creates a structural shift from ex vivo to in vivo CAR‑T approaches, potentially simplifying manufacturing and accelerating clinical translation. That broadens Cartesian’s platform, reduces manufacturing complexity for select programs, and can lower long‑term cost and time to market.
Read all positive factors
Cartesian Therapeutics (RNAC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$279.42M
Dividend YieldN/A
Average Volume (3M)314.08K
Price to Earnings (P/E)―
Beta (1Y)2.62
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees66
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.79
Shares Outstanding29,381,514
10 Day Avg. Volume575,948
30 Day Avg. Volume314,080
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue64.65
Enterprise Value/Gross Profit-10.41
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$33.83Price Target Upside380.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.15
Revenue Forecast (FY)$549.50K
Cartesian Therapeutics Business Overview & Revenue Model
Company Description
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the advancement and discovery of nanoparticle-based immunomodulatory drugs. These innovative therapeutics are designed to both treat and prevent a variety o...
How the Company Makes Money
null...
Cartesian Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.77M | 2.80M | 38.91M | 26.00M | 110.78M | 85.08M |
| Gross Profit | -11.02M | 2.80M | 38.91M | 26.00M | 108.74M | 85.08M |
| EBITDA | -159.77M | -139.50M | -75.99M | -235.03M | 39.84M | -5.16M |
| Net Income | -151.77M | -130.30M | -77.42M | -219.71M | 35.38M | -25.69M |
Balance Sheet | ||||||
| Total Assets | 288.39M | 296.41M | 435.02M | 305.05M | 165.89M | 159.88M |
| Cash, Cash Equivalents and Short-Term Investments | 118.64M | 125.14M | 212.61M | 76.91M | 134.60M | 128.06M |
| Total Debt | 11.86M | 12.68M | 13.98M | 10.96M | 37.92M | 35.28M |
| Total Liabilities | 436.51M | 422.65M | 441.82M | 745.23M | 72.06M | 137.36M |
| Stockholders Equity | -148.12M | -126.24M | -6.80M | -440.18M | 93.83M | 22.52M |
Cash Flow | ||||||
| Free Cash Flow | -77.37M | -79.39M | -32.77M | -51.37M | -32.83M | -61.47M |
| Operating Cash Flow | -72.97M | -73.94M | -23.67M | -51.16M | -31.63M | -60.38M |
| Investing Cash Flow | -4.41M | -5.45M | -8.74M | 34.61M | -15.00M | -17.14M |
| Financing Cash Flow | 15.64M | -8.05M | 168.43M | -13.14M | 39.22M | 52.90M |
Cartesian Therapeutics Technical Analysis
Positive
7.04
Price Trends
6.95
Positive
6.99
Positive
7.72
Positive
Market Momentum
0.19
Negative
68.33
Neutral
68.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAC, the sentiment is Positive. The current price of 7.04 is above the 20-day moving average (MA) of 6.91, above the 50-day MA of 6.95, and below the 200-day MA of 7.72, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 68.33 is Neutral, neither overbought nor oversold. The STOCH value of 68.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNAC.
Cartesian Therapeutics Risk Analysis
Cartesian Therapeutics disclosed 45 risk factors in its most recent earnings report. Cartesian Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cartesian Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $373.09M | 15.28 | 20.37% | ― | -2.38% | -37.13% | |
52 Neutral | $279.42M | -1.68 | 194.13% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $359.32M | -2.10 | -57.01% | ― | ― | -28.75% | |
47 Neutral | $1.03B | -8.90 | -130.06% | ― | ― | 21.76% | |
46 Neutral | $778.11M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
44 Neutral | $211.47M | -1.79 | -55.97% | ― | -45.50% | -35.63% |
* Healthcare Sector Average
RNAC
Cartesian Therapeutics
9.51
-0.81
-7.85%
PBYI
Puma Biotechnology
7.33
3.88
112.46%
DBVT
DBV Technologies SA - American
17.42
7.86
82.36%
VYGR
Voyager Therapeutics
3.50
0.19
5.90%
AVIR
Atea Pharmaceuticals
4.49
1.30
40.75%
VOR
Vor Biopharma
14.36
9.93
224.15%
Cartesian Therapeutics Corporate Events
Business Operations and Strategy
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance
Positive
Jun 9, 2026
On June 9, 2026, Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases by combining Cartesian’s mRNA payloads, including Descartes-08, with WestGen...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Cartesian Secures Major Loan Facility to Extend Runway
Positive
May 26, 2026
On May 22, 2026, Cartesian Therapeutics entered into a senior secured loan and security agreement with K2 HealthVentures and other lenders for a credit facility of up to $150 million, including an initial $50 million tranche funded at closing and ...
Executive/Board Changes
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
Neutral
Mar 30, 2026
On March 26, 2026, Cartesian Therapeutics, Inc. disclosed that Board member Murat Kalayoglu, M.D., Ph.D., intends to resign from the Board effective March 31, 2026, after serving since 2023. Kalayoglu, who chaired the Science and Technology Commit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.